"Intra-Seasonal Waning" as Methodological Artifact

Ivo M. Foppa

10/10/2018

Waning VE

- Since 2015, there have been numerous reports, from the US, Europe and beyond, suggesting that influenza Vaccine effectiveness (VE) declines over the season
- ..

Petrie JG et al., "Modest waning of influenza vaccine efficacy and antibody titers during the 2007-2008 influenza season", *JID* 2016;214(8):





Figure 2. Influenza Vaccine Effectiveness by Time

Gherasim A et al., "Waning protection of influenza vaccine against mild laboratory confirmed influenza A (H3N2) and B in Spain, season 2014-15", *Vaccine* 2016;34(20):



¹ IVE adjusted by sex, age (0-14: 15-64: 9-64 years), chronic condition, sentinel network, period of swabbing (pre-epidemic -weeks 50/02/14-01/1265 epidemic -weeks 2-11/2015), post-epidemic weeks 12-16/2015, obesity, severity, sentinel physicians visits and smoking (prepancy not included due to low sample size: one and two pregnancies in the AffSN2) and B analysis respectively

² IVE modeled with the time since vaccination divided by tertiles and using non-vaccinated as the reference group.

"Even if the vaccine effect does not wane over time, then such waning will nonetheless appear to occur in most studies [...]" ("leaky" vaccines)

"Even if the vaccine effect does not wane over time, then such waning will nonetheless appear to occur in most studies [...]" ("leaky" vaccines)

This will happen if:

"Even if the vaccine effect does not wane over time, then such waning will nonetheless appear to occur in most studies [...]" ("leaky" vaccines)

This will happen if:

 "there is heterogeneous risk of becoming infected within those who are vaccinated"

"Even if the vaccine effect does not wane over time, then such waning will nonetheless appear to occur in most studies [...]" ("leaky" vaccines)

This will happen if:

- "there is heterogeneous risk of becoming infected within those who are vaccinated"
- 2. "some trial participants during the course of the trial become infected but are not counted as cases"

"Even if the vaccine effect does not wane over time, then such waning will nonetheless appear to occur in most studies [...]" ("leaky" vaccines)

This will happen if:

- "there is heterogeneous risk of becoming infected within those who are vaccinated"
- "some trial participants during the course of the trial become infected but are not counted as cases" ← Not relevant to TND studies!

"Even if the vaccine effect does not wane over time, then such waning will nonetheless appear to occur in most studies [...]" ("leaky" vaccines)

This will happen if:

- "there is heterogeneous risk of becoming infected within those who are vaccinated"
- "some trial participants during the course of the trial become infected but are not counted as cases" ← Not relevant to TND studies!
- 3. What if the vaccine is not leaky?

Vaccine models

• "Leaky" model: Those susceptible before vaccination have a risk of $\lambda_0 k$ of becoming infected during a contact if an unvaccinated susceptible has risk λ_0 .

Approach

 Simulation of seasonal influenza epidemics using simple SIR ODE models

- Simulation of seasonal influenza epidemics using simple SIR ODE models
- Implement two scenarios ("leaky", "all-or-none" with two viruses)

- Simulation of seasonal influenza epidemics using simple SIR ODE models
- Implement two scenarios ("leaky", "all-or-none" with two viruses)
- Use numerical solutions to ODEs to generate TND data

- Simulation of seasonal influenza epidemics using simple SIR ODE models
- Implement two scenarios ("leaky", "all-or-none" with two viruses)
- Use numerical solutions to ODEs to generate TND data
- Calculate VE "estimates" and true VE

"Leaky" vaccine: The instantaneous infection risk of those vaccinated is reduced by a constant factor (e.g. difference in infectious dose):

⁻ Methdological sources of "waning effect"

First scenario: "Leaky" vaccine

"Leaky" vaccine: The instantaneous infection risk of those vaccinated is reduced by a constant factor (e.g. difference in infectious dose):

Risk at time t in those not vaccinated:

$$\lambda_0(t)$$

Risk at time t in those vaccinated:

$$\lambda_1(t) = \lambda_0(t) \alpha; \ \alpha \in [0, 1]$$

"Leaky" vaccine: The instantaneous infection risk of those vaccinated is reduced by a constant factor (e.g. difference in infectious dose):

Risk at time t in those not vaccinated:

$$\lambda_0(t)$$

Risk at time t in those vaccinated:


$$\lambda_1(t) = \lambda_0(t) \ \alpha; \ \alpha \in [0, 1]$$

$$ightharpoonup$$
 VE = 1 $-rac{\lambda_1(t)}{\lambda_0(t)}$ = 1 $-rac{\lambda_0(t)}{\lambda_0(t)}$ = 1 $-lpha$

Deterministic transmission modeling, refresher


Deterministic transmission modeling, refresher

Basic SIR model



Deterministic transmission modeling, refresher

Basic SIR model




Differential equation representation (Kermack&McKendrick, 1927):

$$\frac{dS}{dt} = -\beta I \cdot \frac{dI}{dt} = \beta I S \cdot \frac{dR}{dt} = -\gamma I \cdot \frac{dR}{dt}$$

Deterministic transmission modeling, refresher

Basic SIR model




Differential equation representation (Kermack&McKendrick, 1927):

$$\begin{aligned} \frac{dS}{dt} &= -\beta IS \\ \frac{dI}{dt} &= \beta IS \\ \frac{dR}{dt} &= -\gamma I \end{aligned}$$

System of ODEs can be solved (numerically!), makes pretty pictures ...


SIR model, "leaky" vaccine



where
$$\lambda(t) = \beta(I_v + I_{nv})$$
.


VE estimates for true VE=50%

VE Estimates by True VE



VE estimates for true VE=50%


VE Estimates by True VE



Day


VE estimates for range of true VEs

VE Estimates by True VE



Day

VE estimates for range of true VEs



Mechanism for reduced VE over season, "leaky" vaccine

- True VE remains unchanged
- Decrease in VE due to bias: Faster depletion of unvaccinated susceptibles, compared to vaccinated susceptibles

⁻ Methdological sources of "waning effect"


First scenario: "Leaky" vaccine

"All-Or-None" Vaccine, two viruses: Vaccination fully immunizes against virus 2; infection with either virus immunizes fully:

⁻ Methdological sources of "waning effect"

Second scenario: "All-or-none", two viruses

"All-Or-None" Vaccine, two viruses: Vaccination fully immunizes against virus 2; infection with either virus immunizes fully:




⁻ Methdological sources of "waning effect"

Second scenario: "All-or-none", two viruses

Second scenario: "All-or-none", two viruses

"All-Or-None" Vaccine, two viruses: Vaccination fully immunizes against virus 2; infection with either virus immunizes fully:



$$VE(t) = 1 - \frac{\lambda_1(t)}{\lambda_0(t)}$$


$$= 1 - \frac{\beta_1(I_{v1} + I_{nv1})}{\beta_1(I_{v1} + I_{nv1}) + \beta_2 I_{nv2}} \rightarrow \text{time dependent; both viruses}$$

Waning

Methdological sources of "waning effect"

Second scenario: "All-or-none", two viruses


VE estimates over season



Waning

- Methdological sources of "waning effect"
 - Second scenario: "All-or-none", two viruses


VE estimates over season



Waning

- Methdological sources of "waning effect"
 - Second scenario: "All-or-none", two viruses

VE estimates over season




Mechanisms for reduced VE over season, "all-or-none" vaccine, two viruses

- ► True decrease in VE due to evolutionary process, without any decay in individual vaccine protection: Relative distribution of two viruses changes (virus 1 outcompeting virus 2)
- Decrease in VE due to bias: Faster depletion of unvaccinated susceptibles, compared to vaccinated susceptibles.

⁻ Methdological sources of "waning effect"

Second scenario: "All-or-none", two viruses

Evolutionary process: Viruse 1 outcompeting virus 2



Second scenario: "All-or-none", two viruses

Outlook: How to deal with these issues?

Outlook: How to deal with these issues?

